A groundbreaking vaccine, designed entirely by artificial intelligence, has entered human trials at the University of Cambridge, marking a potential turning point in pandemic prevention. Unlike traditional vaccines that target specific strains, this AI-driven approach aims to establish immunity against a broad spectrum of viruses, including all known coronaviruses. The initial phase of trials involved 39 participants and focused on safety, with promising results prompting plans for a larger study involving approximately 200 individuals to evaluate immune response. Researchers utilized genetic data from coronaviruses to create a 'super-antigen' that equips the immune system to combat various viral mutations. Experts, including Professor Jonathan Heeney, believe this methodology could revolutionize vaccine development, enabling protection against future outbreaks. The technology is also being applied to develop vaccines for other diseases, such as a universal flu vaccine and H5N1 bird flu. While the results are encouraging, experts stress that human trials will be crucial for confirming efficacy, with AI viewed as a game changer in the field of vaccine research.